Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionAPG Asset Management N.V.
Latest Disclosed Ownership51,159 shares
Latest Disclosed Value $ 5,849,407
APG Asset Management N.V. reports 13.71% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 13, 2026 - APG Asset Management N.V. filed a 13F-HR form disclosing ownership of 51,159 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $5,849,407 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 59,288 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -13.71% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 51,159 -8,129 -13.71 5,849 -18.30 0.0185
2026-02-12 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 59,288 -1,720 -2.82 7,160 -1.77 0.0203
2025-11-12 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 61,008 430 0.71 7,289 12.37 0.0205
2025-08-12 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 60,578 2,636 4.55 6,486 9.34 0.0192
2025-05-14 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 57,942 -2,247 -3.73 5,933 -25.23 0.0184
2025-02-13 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 60,189 60,189 7,934 0.0221
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -257,315 -100.00 0 -100.00
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 257,315 -119,803 -31.77 33,053 -31.37 0.0590
2024-05-14 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 377,118 -5,426 -1.42 48,159 5.55 0.0844
2024-02-13 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 382,544 46,685 13.90 45,629 20.76 0.0890
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 335,859 21,378 6.80 37,784 39.01 0.0773
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 314,481 -12,265 -3.75 27,182 -10.71 0.0548
2023-05-12 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 326,746 15,466 4.97 30,442 82,172.97 0.0646
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 311,280 76,960 32.84 37 -99.85 0.0707
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 234,320 -89,056 -27.54 25,404 -15.75 0.0655
2022-08-12 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 323,376 1,466 0.46 30,152 11.16 0.0707
2022-05-12 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 321,910 -600 -0.19 27,124 12.30 0.0513
2022-02-11 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 322,510 314,900 4,137.98 24,154 3,733.97 0.0410
2021-11-15 2021-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 7,610 -1,500 -16.47 630 -15.78 0.0011
2021-11-15 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,610 -1,500 630 0.0011
2021-08-13 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,110 -109,346 -92.31 748 -92.37 0.0013
2021-05-14 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 118,456 -47,837 -28.77 9,802 -24.76 0.0167
2021-02-12 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 166,293 -20,695 -11.07 13,027 -15.04 0.0212
2020-11-12 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 186,988 45,409 32.07 15,333 -0.30 0.0265
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 141,579 40,000 39.38 15,379 74.92 0.0280
2020-05-19 2020-03-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 101,579 46,579 84.69 8,792 66.93 0.0172
2020-05-15 2020-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 101,579 0 8,792 0.0174
2020-02-13 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 55,000 55,000 5,267 0.0086
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.